Wealthfront Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.94M | Buy |
12,084
+3,363
| +39% | +$1.1M | 0.01% | 425 |
|
|
2025
Q1 | $2.35M | Sell |
8,721
-3,899
| -31% | -$1.05M | 0.01% | 500 |
|
|
2024
Q4 | $2.97M | Buy |
12,620
+4,324
| +52% | +$1.02M | 0.01% | 434 |
|
|
2024
Q3 | $2.28M | Buy |
8,296
+200
| +2% | +$55K | 0.01% | 473 |
|
|
2024
Q2 | $1.97M | Buy |
8,096
+6
| +0.1% | +$1.46K | 0.01% | 484 |
|
|
2024
Q1 | $1.21M | Sell |
8,090
-3,495
| -30% | -$522K | ﹤0.01% | 578 |
|
|
2023
Q4 | $2.22M | Sell |
11,585
-772
| -6% | -$148K | 0.01% | 440 |
|
|
2023
Q3 | $2.19M | Sell |
12,357
-15,289
| -55% | -$2.71M | 0.01% | 405 |
|
|
2023
Q2 | $5.25M | Sell |
27,646
-6,667
| -19% | -$1.27M | 0.02% | 205 |
|
|
2023
Q1 | $6.87M | Buy |
34,313
+1,727
| +5% | +$346K | 0.03% | 161 |
|
|
2022
Q4 | $7.74M | Buy |
32,586
+14,210
| +77% | +$3.38M | 0.04% | 141 |
|
|
2022
Q3 | $3.68M | Buy |
18,376
+4,258
| +30% | +$852K | 0.02% | 237 |
|
|
2022
Q2 | $2.06M | Buy |
14,118
+1,273
| +10% | +$186K | 0.01% | 375 |
|
|
2022
Q1 | $2.1M | Buy |
12,845
+11,526
| +874% | +$1.88M | 0.01% | 391 |
|
|
2021
Q4 | $224K | Buy |
+1,319
| New | +$224K | ﹤0.01% | 731 |
|